Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells

Molecular Cancer Therapeutics

Volumn 8, Issue 12, 2009, Pages 3214-3222

  Cui, Jian ^a   Wang, Qingyang ^a   Wang, Jing ^a   Lv, Ming ^a   Zhu, Ning ^a   Li, Yan ^a   Feng, Jiannan ^a   Shen, Beifen ^a   Zhang, Jiyan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

(1,3 BENZOTHIAZOL 2 YL)[2 [2 (3 PYRIDINYL)ETHYLAMINO] 4 PYRIMIDINYL]ACETONITRILE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PROTEIN BCL 2; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL NUCLEUS; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA;

ACETONITRILES; ANIMALS; ANTHRACENES; APOPTOSIS; BENZOTHIAZOLES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JURKAT CELLS; MAP KINASE KINASE 7; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; TRANSFECTION;

EID: 73149095394     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0408     Document Type: Article

References (37)

1. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993;7:2135-48.
2. Chang L, Karin M. Mammalian MAP kinase signaling cascades. Nature 2001;410:37-40.
3. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007;19:1-8.
4. Lin A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 2003;25:1-8.
5. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-6.
6. Yu C, Minemoto Y, Zhang J, et al. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 2004; 13:329-40.
7. 2-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 2002;62:1343-8.
8. Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 2007;26:3172-84.
9. 2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 2005;65:10984-91.
10. 2-terminal kinase in transformed B lymphoblasts. Nat Genet 2002;32:201-5.
11. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005;106:1382-91.
12. 2-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 2003;22:8797-801.
13. Leventaki V, Drakos E, Medeiros LJ, et al. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood 2007;110:1621-30.
14. Arnulf B, Villemain A, Nicot C, et al. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-β1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002; 100:4129-38.
15. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al. Jak3- and JNKdependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006;20:1759-66.
16. Zientek-Targosz H, Kunnev D, Hawthorn L, et al. Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: a model for identifying candidate breast-tumor suppressors. Mol Cancer 2008;7:51.
17. Zhang J, Shen B, Li Y, Sun Y. STAT3 exerts two-way regulation in the biological effects of IL-6 in M1 leukemia cells. Leuk Res 2001;25:463-72.
18. Zheng C, Xiang J, Hunter T, Lin A. The MKK7-1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity. J Biol Chem 1999;274:28966-71.
19. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001; 98:13681-6.
20. 2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther 2004;310:25-32.
21. 2-terminal kinase (JNK) inhibitor, reduces axon/ dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol 2008;153:157-63.
22. Wang J, Minemoto Y, Lin A, Li Y, Shen B, Zhang J. IKK antagonizes CD95 ligation-mediated apoptosis by regulating NF-κB activity. Mol Immunol 2007;44:2139-43.
23. Low W, Smith A, Ashworth A, Collins M. JNK activation is not required for Fas-mediated apoptosis. Oncogene 1999;18:3737-41.
24. O'Gorman DM, McKenna SL, McGahon AJ, Cotter TG. Inhibition of PI3-kinase sensitizes HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a JNK independent pathway. Leuk Res 2001;25:801-11.
25. 2/M cell cycle arrest. Cancer Res 2005;65:6780-8.
26. Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT. Cre/lox-regulated transgenic zebrafish model with conditional mycinduced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2005;102:6068-73.
27. Langenau DM, Traver D, Ferrando AA, et al. Myc-induced T cell leukemia in transgenic zebrafish. Science 2003;299:887-90.
28. Zhou M, Gu L, Yeager AM, Findley HW. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 1998;12:1756-63.
29. Mignon A, Guidotti JE, Mitchell C, et al. Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes. Nat Med 1998;4: 1185-8.
30. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominantnegative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 2001;29: 629-43.
31. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 2006;70: 1061-95.
32. Zhang S, Lin Y, Kim YS, Hande MP, Liu ZG, Shen HM. c-Jun N-terminal kinase mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose) polymerase-1 activation. Cell Death Differ 2007;14: 1001-10.
33. Lu C, Zhu F, Cho YY, et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell 2006;23:121-32.
34. Hui L, Bakiri L, Mairhorfer A, et al. p38α suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007;39:741-9.
35. Guo L, Guo Y, Xiao S, Shi X. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci 2005;77:1869-78.
36. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007;26:3100-12.
37. Liu J, Minemoto Y, Lin A. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor α-induced c-Jun kinase activation and apoptosis. Mol Cell Biol 2004;24:10844-56.